On January 20th, JIN10 News reported that Connoa and NovaQuest jointly announced that the two companies and their joint venture have reached a licensing agreement with Prolium Bioscience, authorizing Prolium to develop and commercialize the CD20×CD3 bispecific antibody ICP-B02 (CM355). According to the protocol, Prolium will have the rights to develop, register, produce, and commercialize ICP-B02 in the global non-oncology field and the oncology field outside of Asia. NovaQuest and Connoa will receive a total payment of up to $520 million, including upfront and near-term payments, as well as additional payments for achieving clinical development, registration, and commercialization milestones, and both parties will receive a minority equity stake in Prolium. In addition, NovaQuest and Connoa will also receive tiered royalty payments based on future net sales of the product.
Disclaimer: The information on this page may come from third parties and does not represent the views or opinions of Gate. The content displayed on this page is for reference only and does not constitute any financial, investment, or legal advice. Gate does not guarantee the accuracy or completeness of the information and shall not be liable for any losses arising from the use of this information. Virtual asset investments carry high risks and are subject to significant price volatility. You may lose all of your invested principal. Please fully understand the relevant risks and make prudent decisions based on your own financial situation and risk tolerance. For details, please refer to
Disclaimer.
